Protelos, first in new class of osteoporosis therapies launched today

Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.

Recent Blog Post

The Link Between Gut Viruses and Cardiometabolic Disease 

21st February 2024 – By TwinsUK A recent review published by researchers at TwinsUK sheds light on the potential role...

The gut microbiome can predict treatment response in rheumatoid arthritis

Monday 19th February – by King’s College London Professor Frances Williams’ chronic pain research group within TwinsUK at King’s College...

MRI scanner and researchers

TwinsUK Twins Undergo First MRI Scan in New Study on Healthy Ageing 

19th January 2024 – By Aaruthy Suthahar TwinsUK and the School of Biomedical Engineering & Imaging Sciences at King’s College...